Treatment adherence in schizophrenia. Spanish clinical consensus.
Objective. Establish a Spanish Consensus on Therapeutic Compliance in Schizophrenia.<p> Material and methods. An experts committee designed a specific questionnaire having 40 questions and 293 options. The questions referred to the definition and general assessment of compliance in schizophrenia, factors involved, intervention strategies in outpatients and in acute units and management of oral and long duration injectable antipsychotic drugs and other non-pharmacological therapies. First, second or third line strategy values of choice were assigned according to the answers obtained for each item. The questionnaire was sent to 383 psychiatrists of a Therapeutic Compliance Work Group. A total of 326 answers were received with an electronic system that guaranteed their confidentiality.</p><p> Results and conclusions. There is maximum agreement on considering the seriousness of the compliance problem, its repercussion in relapses, the patient's course and increase in health care costs. The strategies preferred to evaluate compliance are: counting of the injectable drug administration and determination of plasma concentrations. The Consensus considers that specific intervention is necessary when the patient has already suffered several relapses due to low therapeutic compliance, when null awareness of disease is detected or if there is comorbidity with toxic consumption. Psychoeducational is the non-pharmacological strategy having the greatest consensus grade if intervention is needed. Treatments with atypical injectable, long duration, antipsychotic drugs obtain the best grade in accordance with pharmacological strategies of first choice, in different clinical situations to avoid or improve therapeutic adherence.</p><p> Key words:<br /> Adherence. Compliance. Schizophrenia. Consensus.</p>
Roca
M
M
Unidad de Psiquiatría. Hospital Juan March. Institut Universitari d’Investigació en Ciències de la Salut (IUNICS). Universitat de les Illes Balears. Palma de Mallorca.
Cañas
F
F
Olivares
Jm
J
Rodríguez
A
A
Giner
J
J
D014150:Antipsychotic Agents / Q000627:therapeutic use; D015897:Comorbidity; D032921:Consensus; D006801:Humans; D055118:Medication Adherence; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents